Urology · Lancaster, PA
NPI
1851375026
Since 2005
Specialty
Urology
Code 208800000X
Group practices
2
Medicare group memberships
Hospitals
4
Hospital affiliations
2106 Harrisburg Pike, Suite 200
Lancaster, PA, 17601
Phone (717) 393-1771
Groups this clinician bills Medicare through
Medicare paid, 2024
$1.2M
19,831 services
Medicare patients, 2024
782
Average age 77
Drug cost, 2024
$7.5M
3,619 prescriptions
Company payments, 2025
$116K
From 27 companies
Procedures and visits billed to Original Medicare, 2024
In 2024, the most common Medicare service billed by Paul R Sieber was code J0897 (injection, denosumab, 1 mg), 8,820 times for 52 patients. In total Paul R Sieber billed 19,831 services in 70 codes, and Medicare paid $1.2M.
| Code |
|---|
Official US government data: the national provider registry and Medicare enrollment records, linked by NPI. Last update of this record: 2007-08-21.
| Setting |
|---|
| Services |
|---|
| Patients |
|---|
| Paid per service |
|---|
| Medicare paid |
|---|
| J0897 Injection, denosumab, 1 mg | Office | 8,820 | 52 | $20.62 | $182K |
| J1952 Leuprolide injectable, camcevi, 1 mg | Office | 3,066 | 54 | $43.74 | $134K |
| Q9967 Low osmolar contrast material, 300-399 mg/ml iodine concentration, per ml | Office | 3,025 | 24 | $0.10 | $296 |
| 99214 Office E&M - Established | Office | 795 | 400 | $82.95 | $66K |
| G2211 Visit complexity inherent to evaluation and management associated with medical care services that serve as the continuing focal point for all needed health care services and/or with medical care services that are part of ongoing care related to a patient's | Office | 730 | 416 | $11.60 | $8,465 |
| 99213 Office E&M - Established | Office | 379 | 339 | $58.13 | $22K |
| 81003 Clinical Chemistry | Office | 315 | 261 | $2.19 | $689 |
| 81001 Clinical Chemistry | Office | 278 | 239 | $3.07 | $853 |
| 36415 Venipuncture Blood Collection | Office | 172 | 113 | $8.55 | $1,471 |
| 84153 Clinical Chemistry | Office | 120 | 83 | $17.72 | $2,126 |
| 96372 Injection Administration | Office | 98 | 53 | $9.71 | $952 |
| 96402 Chemotherapy Administration | Office | 79 | 57 | $25.02 | $1,977 |
| 84403 Clinical Chemistry | Office | 74 | 44 | $24.95 | $1,846 |
| 51798 Ultrasound - Nonspecific | Office | 62 | 61 | $7.54 | $468 |
| 51702 Other Organ Systems | Office | 59 | 17 | $40.98 | $2,418 |
By year: 2022 $1.9M for 26,446 services; 2023 $1.7M for 24,884 services; 2024 $1.2M for 19,831 services.
Lab tests billed to Medicare, 2024
| Test code | Tests | Patients | Paid per test | Medicare paid |
|---|---|---|---|---|
| 81003 Clinical Chemistry | 315 | 261 | $2.19 | $689 |
| 81001 Clinical Chemistry | 278 | 239 | $3.07 | $853 |
| 36415 Venipuncture Blood Collection | 172 | 113 | $8.55 | $1,471 |
| 84153 Clinical Chemistry | 120 | 83 | $17.72 | $2,126 |
| 84403 Clinical Chemistry | 74 | 44 | $24.95 | $1,846 |
Medicare prescription drug claims, 2024
In 2024, the drug Paul R Sieber prescribed most often to Medicare patients was Finasteride, with 535 prescriptions and refills. In total Paul R Sieber wrote 3,619 Medicare prescriptions that cost $7.5M.
| Drug | Claims | 30-day fills | Patients | Cost |
|---|---|---|---|---|
| Finasteride Generic | 535 | 1,552 | 172 | $7,387 |
| Abiraterone Acetate Generic | 525 | 525 | 65 | $413K |
| Tamsulosin Hcl Generic | 494 | 1,302 | 150 | $9,364 |
| Orgovyx Relugolix | 389 | 389 | 56 | $1.0M |
| Prednisone Generic | 254 | 576 | 66 | $1,931 |
| Xtandi Enzalutamide | 194 | 200 | 32 | $2.5M |
| Dutasteride Generic | 115 | 297 | 33 | $5,084 |
| Nubeqa Darolutamide | 107 | 107 | 17 | $1.3M |
| Myrbetriq Mirabegron | 105 | 224 | 30 | $97K |
| Levofloxacin Generic | 90 | 90 | 79 | $85.42 |
| Alfuzosin Hcl Er Alfuzosin Hcl | 67 | 201 | 20 | $1,866 |
| Lynparza Olaparib | 55 | 55 | Under 11 | $788K |
| Erleada Apalutamide | 52 | 52 | Under 11 | $738K |
| Cephalexin Generic | 38 | 108 | 15 | $1,044 |
| Gemtesa Vibegron | 35 | 45 | Under 11 | $22K |
Brand drugs: 1,011 claims; generic drugs: 2,608 claims; opioid claims: 24.
Money and other things of value reported by the companies
In 2025, drug and medical device companies paid Paul R Sieber $116K ($111K in general payments such as food, travel and fees and $5,223 for research) from 27 companies. The largest payer was Pfizer Inc. with $22K.
| Company | Payments | Amount |
|---|---|---|
| Pfizer Inc. PFE | 41 | $22K |
| Merck Sharp & Dohme LLC MRK | 17 | $21K |
| Accord Healthcare, Inc. | 7 | $20K |
| Dendreon Pharmaceuticals LLC | 35 | $19K |
| Astellas Pharma US Inc 4503.T | 18 | $13K |
| Bayer Healthcare Pharmaceuticals Inc. BAYN.DE | 17 | $6,907 |
| Janssen Biotech, Inc. JNJ | 18 | $6,610 |
| Avyxa Pharma, LLC | 6 | $4,086 |
| Ferring Pharmaceuticals Inc. | 3 | $2,825 |
| Novartis Pharmaceuticals Corporation NVS | 4 | $269 |
Official US government data on Original Medicare services, Medicare prescription drug plans and the payments drug and device companies must report. Services with fewer than 11 patients and drugs with fewer than 11 claims are not published. Procedure codes are shown by number with their public category.